Joseph A. Cucolo to join Rex Bionics Board

Rex Bionics Plc

("Rex Bionics" or the "Company")

Joseph A. Cucolo to join Rex Bionics Board of Directors

11 January 2016: Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheelchair users, is pleased to announce the appointment of Joseph A. Cucolo as a Non-executive Director of the Company.

Joe Cucolo has had a long and successful career with Zimmer Holdings Inc., one of the largest medical device companies in the world, latterly as President of Americas with responsibility for a $2.5 billion business covering the United States, Canada and Latin America. He left Zimmer in 2015 to pursue new business interests following Zimmer's acquisition of its major competitor, Biomet. Earlier in his career, Joe was the sole owner and President of Zimmer New England, an independent distributorship in the northeast region of the United States.

Joe is a US citizen and lives in upstate New York.

David Macfarlane, Chairman of Rex Bionics Plc, commented: "We are delighted that Joe has agreed to join the Rex Bionics Board. Joe's sales and marketing experience, his track record and his extensive network will be tremendously valuable to the development of our business, especially in the US. I look forward to working closely with Joe and to benefiting from his contribution to our Board." 

Joe Cucolo added: "I am pleased and excited to be joining the Rex Bionics team and for the opportunity to continue to offer state of the art technology that allows patients increased mobility and quality of life, one individual at a time. The REX Robot is impressive, cutting edge technology for which I see huge potential in the US market. It represents an opportunity to establish a completely new paradigm in neuro-rehabilitation therapy."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies: Joseph Anthony Cucolo, aged 56 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

Nil

Past directorships

Nil

The following information is disclosed pursuant to Rule 17 of the AIM Rules for Companies: Mr Cucolo currently holds no shares in Rex Bionics Plc.

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 748 3 167851

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

 Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/Stewart Wallace

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

[email protected]

+44 (0) 203 709 5700

About Rex Bionics plc

Rex Bionics (AIM: RXB) is the pioneer of the REX Robot that enhances the mobility of wheelchair users and was founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs.

Rex Bionics is working with physiotherapists to develop the concept and practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

In addition, REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options. Our vision is to commercialise an all-day use REX P for a target market segment of wheel chair users with a spinal cord injury, who number around 500,000 people in the US and EU alone.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep and maintenance of joint range, and a reduction in spasm, pain, common abdominal problems and prescription drug use.

A program of "RAPPER" clinical trials is now under way to evaluate these potential benefits and a positive interim analysis of the RAPPER II data was presented on 27th November 2015. Recruitment for RAPPER II remains open and clinics and individuals can send enquiries to [email protected].

Until now, REX has most commonly been used by wheelchair users with a spinal cord injury, but has also been used by people who have suffered a stroke or other traumatic brain injury; and wheelchair users with multiple sclerosis, muscular dystrophy and cerebral palsy.

Rex Bionics has three Strategic Objectives - to establish Robot-Assisted Physiotherapy as a Gold Standard of Care for Spinal Cord Injury, Stroke and other neurological conditions; to establish REX as the market-leading robotic mobility aid; and by effective execution of our plans, to deliver significant value growth to shareholders.

Rex Bionics works with distribution partners in the US ([email protected]), China (MAAB, [email protected]), Hong Kong and Taiwan (Deltason, [email protected]), Denmark and Belgium; and in other countries we support customers directly ([email protected]).

Rex Bionics was admitted to trading on the London Stock Exchange's AIM in 2014. REX is not registered for At-Home use in the United States of America.